Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol (cas 131918-61-1)

Add time:07/30/2019    Source:sciencedirect.com

IntroductionChronic kidney disease is a major public health problem. In the last decade, it has been shown that the early stages of chronic kidney disease are associated with an inflammatory condition involving an increased risk of cardiovascular morbidity and long-term mortality. In patients with chronic kidney disease and more specifically those on hemodialysis, cardiovascular events are the most common cause of death. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase and may be an independent risk factor for endothelial dysfunction and cardiovascular disease.

We also recommend Trading Suppliers and Manufacturers of Paricalcitol (cas 131918-61-1). Pls Click Website Link as below: cas 131918-61-1 suppliers

Prev:Perfil antiinflamatorio del Paricalcitol (cas 131918-61-1) en el receptor de trasplante renal
Next:Paricalcitol (cas 131918-61-1) Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients)